Bay Colony Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.18M | Sell |
8,670
-66
| -0.8% | -$14.2K | 0.24% | 86 |
|
|
2026
Q1 | $1.9M | Buy |
8,736
+475
| +6% | +$105K | 0.23% | 97 |
|
|
2025
Q4 | $1.89M | Buy |
8,261
+19
| +0.2% | +$4.33K | 0.23% | 91 |
|
|
2025
Q3 | $1.91M | Sell |
8,242
-68
| -0.8% | -$13.8K | 0.23% | 95 |
|
|
2025
Q2 | $1.54M | Sell |
8,310
-35
| -0.4% | -$6.5K | 0.21% | 97 |
|
|
2025
Q1 | $1.71M | Sell |
8,345
-2,167
| -21% | -$421K | 0.26% | 82 |
|
|
2024
Q4 | $1.87M | Buy |
10,512
+16
| +0.2% | +$2.94K | 0.28% | 76 |
|
|
2024
Q3 | $2.07M | Sell |
10,496
-5
| -0% | -$933 | 0.31% | 70 |
|
|
2024
Q2 | $1.8M | Sell |
10,501
-16
| -0.2% | -$2.65K | 0.3% | 72 |
|
|
2024
Q1 | $1.92M | Sell |
10,517
-462
| -4% | -$79.6K | 0.34% | 68 |
|
|
2023
Q4 | $1.7M | Buy |
10,979
+1,642
| +18% | +$239K | 0.33% | 71 |
|
|
2023
Q3 | $1.39M | Sell |
9,337
-3,705
| -28% | -$544K | 0.33% | 72 |
|
|
2023
Q2 | $1.76M | Buy |
13,042
+541
| +4% | +$79.3K | 0.42% | 61 |
|
|
2023
Q1 | $1.97M | Sell |
12,501
-612
| -5% | -$93.6K | 0.52% | 46 |
|
|
2022
Q4 | $2.12M | Sell |
13,113
-642
| -5% | -$98.4K | 0.56% | 40 |
|
|
2022
Q3 | $1.85M | Sell |
13,755
-548
| -4% | -$78.6K | 0.55% | 36 |
|
|
2022
Q2 | $2.05M | Buy |
14,303
+1,299
| +10% | +$198K | 0.52% | 40 |
|
|
2022
Q1 | $2.11M | Sell |
13,004
-3,985
| -23% | -$579K | 0.5% | 49 |
|
|
2021
Q4 | $2.3M | Sell |
16,989
-453
| -3% | -$53.5K | 0.66% | 35 |
|
|
2021
Q3 | $1.88M | Buy |
17,442
+117
| +0.7% | +$13.4K | 0.62% | 41 |
|
|
2021
Q2 | $1.95M | Buy |
17,325
+212
| +1% | +$23.9K | 0.65% | 32 |
|
|
2021
Q1 | $1.85M | Buy |
17,113
+2,569
| +18% | +$275K | 0.71% | 31 |
|
|
2020
Q4 | $1.56M | Sell |
14,544
-975
| -6% | -$93.7K | 0.83% | 22 |
|
|
2020
Q3 | $1.36M | Buy |
15,519
+470
| +3% | +$44.2K | 0.84% | 27 |
|
|
2020
Q2 | $1.48M | Sell |
15,049
-3,030
| -17% | -$267K | 1.07% | 19 |
|
|
2020
Q1 | $1.38M | Buy |
18,079
+3,799
| +27% | +$324K | 1.25% | 12 |
|
|
2019
Q4 | $1.25M | Sell |
14,280
-6,325
| -31% | -$525K | 0.81% | 24 |
|
|
2019
Q3 | $1.56M | Buy |
20,605
+16,784
| +439% | +$1.15M | 1.06% | 11 |
|
|
2019
Q2 | $278K | Buy |
+3,821
| New | +$300K | 0.18% | 156 |
|
|
2018
Q3 | – | Sell |
-990
| Closed | -$92K | – | 217 |
|
|
2018
Q2 | $92K | Buy |
+990
| New | +$96.7K | 0.07% | 263 |
|
Other funds holding ABBV
Bay Colony Advisors's ABBV Position: Q2 2026 in Review
Bay Colony Advisors reduced its AbbVie (ABBV) stake by 0.76% in Q2 2026, selling an estimated $14.2K and leaving 8,670 shares worth $2.18M. The position accounts for 0.24% of the portfolio, ranked #86.
Bay Colony Advisors first reported a position in ABBV in Q2 2018 and has held it in 30 quarters since. The position peaked at $2.3M in Q4 2021. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Bay Colony Advisors held 8,670 shares of AbbVie worth $2.18M as of Q2 2026.
- Bay Colony Advisors sold 66 AbbVie shares in Q2 2026, an estimated $14.2K.
- AbbVie made up 0.24% of Bay Colony Advisors's portfolio in Q2 2026, its #86 holding.
- Bay Colony Advisors first reported a position in AbbVie in Q2 2018 and has held it in 30 quarters since.
- Bay Colony Advisors's AbbVie position peaked at $2.3M in Q4 2021.
- 4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Bay Colony Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.